The day at a glance · 3 min read
Mood · Risk-On
+65
Sentiment, −100 to +100
Eli Lilly 1-year total return
57.3%+57.3%
Big Pharma & Biotech
Regeneron downside risk estimate
16.4%-16.4%
Big Pharma & Biotech
AxoGen Q3 EPS surprise
+50.00%+50.00%
MedTech & Devices
Key driverEli Lilly's positive Phase 3 head-to-head trial results for retatrutide versus Ozempic in type 2 diabetes drove optimism across the GLP-1 and metabolic disease space
Daily briefHealthcare· Money365.Market AI ·

Lilly Retatrutide Tops Ozempic; Dexcom Expands in Canada

Eli Lilly's retatrutide delivered superior A1C reduction and weight loss versus Ozempic in head-to-head trial; DexCom launches 15-day CGM in Canada

Big Pharma & Biotech

Bullish
01LLY
Eli Lilly (LLY) announced positive topline results from TRANSCEND-T2D-2, a head-to-head Phase 3 trial comparing retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes. At 80 weeks, retatrutide met the primary and all key secondary endpoints, delivering greater A1C reduction and substantially more weight loss than Ozempic. Investors who held Eli Lilly (LLY) over the past year are up 57.3%, including dividends, against a backdrop of huge GLP-1 demand, rich valuation debates, and sharply different analyst targets. The company is scheduled to report earnings tomorrow before market hours.
02ABBV
AbbVie (ABBV) was featured among five high-yield dividend stocks that have kept raising their payouts through every rate spike in recent memory, even as Treasury yields near 5% make dividend stocks work harder to justify their risk. Analysts noted the company spans pharma and other sectors in a portfolio approach for retirement-focused investors.
03BMY
Bristol Myers Squibb (BMY) is set to announce earnings results this Thursday before the bell, with investors awaiting updates on the biopharmaceutical company's performance amid ongoing drug pricing reform discussions and patent risk debates.
04REGN▲ +1.04%
Regeneron Pharmaceuticals (REGN) faces 16.4% downside risk ahead of its earnings report, according to one analysis, as Dupixent growth, EYLEA pressure, and pipeline risks cloud valuation despite the blockbuster franchise's continued expansion.

MedTech & Devices

Neutral

AxoGen Q3 revenue surprise

+4.17%+4.17%

Intuitive Surgical share price

$445.88

Intuitive Surgical 90-day return

26.32%+26.32%

Intuitive Surgical 30-day return

7.50%+7.50%
01DXCM
DexCom (DXCM), the global leader in glucose biosensing, announced that the Dexcom G7 15 Day Continuous Glucose Monitoring System will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear, Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy, giving Canadians living with diabetes more time between sensor changes. The company is scheduled to report Q3 results this Thursday after the bell.
02AXGN
AxoGen (AXGN) delivered earnings and revenue surprises of 50.00% and 4.17%, respectively, for the quarter ended September 2026. The peripheral nerve repair company's strong Q3 performance exceeded analyst expectations across both top and bottom lines.
03ISRG▼ -1.27%
Intuitive Surgical (ISRG) common stock is back in focus after its latest earnings report, which paired higher quarterly revenue with lower net income and earnings per share, giving investors a mixed but important update on performance. At a share price of $445.88, the surgical robotics company has logged a 26.32% 90-day share price return and a 7.50% 30-day share price return, though the year-to-date share price is down 20.66% and the 1-year total shareholder return is down 17.06%, so recent momentum contrasts with longer-term pressure.

Health Insurance & Managed Care

Bullish
01UNH
UnitedHealth Group (UNH) remains a Buy according to one analysis, with growing free cash flow, disciplined capital returns, and a healthy balance sheet supporting the investment thesis. The managed care giant's raised premiums, market exits, and member attrition are positioned to deliver future resilience as the company navigates a challenging regulatory and competitive environment.

Looking Ahead

Neutral
LLYBMYDXCM
01LLY
Three major pharmaceutical companies report earnings this week, with Eli Lilly (LLY) scheduled for Thursday before market hours, Bristol Myers Squibb (BMY) reporting Thursday before the bell, and DexCom (DXCM) announcing Q3 results Thursday after the close. Investor focus will center on GLP-1 demand trends at Lilly, drug pricing impacts and pipeline progress at Bristol Myers, and continuous glucose monitoring adoption at DexCom following the Canadian G7 15 Day launch announcement.
02
Micron Biomedical appointed Anand Subramony, Ph.D., formerly of Lilly and AstraZeneca, as executive vice president for global product development and combination product commercialization, signaling the company's transition from a platform technology to a commercial products company.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy